Inspirata Buys Caradigm From GE Healthcare

June 13, 2018
Cancer informatics and digital pathology workflow company Inspirata Inc. has acquired Redmond, Wash.-based Caradigm from GE Healthcare.

Cancer informatics and digital pathology workflow company Inspirata Inc. has acquired Redmond, Wash.-based Caradigm from GE Healthcare.

Caradigm started as a joint venture between Microsoft and GE Healthcare in 2012, but GE Healthcare bought out Microsoft’s stake in the company in 2016. Last fall healthcare IT firm Imprivata purchased Caradigm's identity and access management solutions. 

The company’s Caradigm Intelligence Platform and population health management software portfolio spans data control; healthcare analytics; and care coordination and engagement across integrated delivery networks, accountable care organizations, clinically integrated networks, academic medical centers and community hospital networks.

The platform aggregates data across clinical, social, operational and financial sources from disparate source systems – electronic health records, billing systems, payers, claims, pharmacy systems, labs and HIEs. Caradigm also provides a suite of applications for improving the patient experience of care, improving the health of populations and reducing the per capita cost of healthcare.

Tampa, Fla.-based Inspirata provides oncology diagnostics workflow solutions that span digital pathology; diagnostic and predictive assays; and precision medicine. It also offers cancer informatics workflows that, in combination with its natural language processing and artificial intelligence algorithms structures unstructured case files and clinician notes to provide key insights for clinical and operational activities as well as cancer reporting.

“Caradigm has built a highly regarded, industry-proven big data health analytics platform,” says Inspirata CEO Satish Sanan, in a prepared statement. “Our goal is to leverage the core strengths of this platform to accelerate our Cancer Information Data Trust (CIDT) development. The CIDT will address key trends in oncology care, providing important new insights for clinicians, researchers, drug discovery and cancer center operations. In addition to this, Caradigm’s strong population health product set and experienced team will have Inspirata’s specialized focus and attention to promote long-term sustainability, growth and innovation as we redouble our focus on delivering superior value to all customers.”

Sponsored Recommendations

How Digital Co-Pilots for patients help navigate care journeys to lower costs, increase profits, and improve patient outcomes

Discover how digital care journey platforms act as 'co-pilots' for patients, improving outcomes and reducing costs, while boosting profitability and patient satisfaction in this...

5 Strategies to Enhance Population Health with the ACG System

Explore five key ACG System features designed to amplify your population health program. Learn how to apply insights for targeted, effective care, improve overall health outcomes...

A 4-step plan for denial prevention

Denial prevention is a top priority in today’s revenue cycle. It’s also one area where most organizations fall behind. The good news? The technology and tactics to prevent denials...

Healthcare Industry Predictions 2024 and Beyond

The next five years are all about mastering generative AI — is the healthcare industry ready?